Our data demonstrated the preliminary therapeutic value of utilizing the novel SIRT3 SUMOylation targeted intervention, such as inhibition of SENP1, to deactivate SIRT3 and re-sensitize AML cells. This evidence concerns the gene SIRT3 and acute myeloid leukemia.